Mr. Bill Adams reports

NERVGEN STRENGTHENS BOARD LEADERSHIP TO ACCELERATE CLINICAL AND CORPORATE GROWTH

Nervgen Pharma Corp. has made changes to its board of directors to support the next phase of growth and further align corporate strategy with the priorities of its shareholders and the SCI community.

Glenn Ives has resigned from Nervgen's board of directors. The board and management thank Mr. Ives for his invaluable contributions and leadership over the past four years. "It has been a privilege to serve as a director and chair during such a pivotal period for Nervgen," said Mr. Ives. "With positive top-line data from our Connect SCI study now in hand, and the complete data set expected soon, I am confident that Nervgen is on a strong path forward to fulfilling its mission of transforming the lives of individuals living with SCI."

The board of directors unanimously appointed Dr. Adam Rogers, a current director and representative of Nervgen's largest shareholder, as the new chair. "Nervgen is at a pivotal juncture, with positive top-line data from our Connect SCI study reinforcing the potential of NVG-291 as both a first-in-class and best-in-class neuroreparative therapy," said Dr. Rogers. "We are actively analyzing and preparing the complete data set from the chronic cohort, and we're excited to build on Nervgen's regulatory and corporate initiatives."

Dr. Rogers is a board-certified physician, biotech entrepreneur and chief executive officer with extensive experience in clinical and regulatory development. He currently serves as managing director of PFP Biosciences, an investment firm focused on breakthrough life sciences technologies, and has been a director at Nervgen since 2022. He also served as Nervgen's interim president from September, 2022, to April, 2023. Previously, Dr. Rogers co-founded and served as CEO of Hemera Biosciences, leading the development of HMR59 (now JNJ-1887), an intraocular gene therapy currently in clinical trials for advanced dry age-related macular degeneration. Dr. Rogers holds an MD and BA from Emory University.

About NVG-291

Nervgen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting nervous system repair. NVG-291's technology is licensed from Case Western Reserve University and is based on academic studies that demonstrated the preclinical efficacy of NVG-291-R, the rodent prototype of NVG-291, in animal models of spinal cord injury. These studies implicated several potential molecular and cellular mechanisms by which NVG-291-R promotes neurorepair and functional improvement in both central and peripheral nervous system injury models. The implicated mechanisms include the promotion of neuronal sprouting, or plasticity, remyelination and promotion of a non-inflammatory phenotype in the microglial cells. Nervgen has received fast-track designation from the Food and Drug Administration) and orphan designation from the EMA for NVG-291 in individuals with spinal cord injury.

About Nervgen Pharma Corp.

Nervgen is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead candidate, NVG-291, in the phase 1b/2a Connect SCI study clinical trial in spinal cord injury. Topline data from the chronic cohort (one to 10 years postinjury) of this trial showed that NVG-291 met its primary end point and demonstrated strong trends in a secondary end point assessing hand function. Complete analysis of the chronic cohort is continuing. Enrolment in the subacute cohort (20 to 90 days postinjury) of the trial continues, and more information about participation in the subacute study is available on-line. In addition, the company has initiated preclinical test of concept evaluation of its pipeline candidate, NVG-300, in models of ischemic stroke and spinal cord injury.

We seek Safe Harbor.